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Abstract The P2X7 purinoceptor is unique amongst the
P2X receptor family in that its activation is able to
stimulate the release of mature, biologically active
interleukin-1β (IL-1β), as well as a variety of other
proinflammatory cytokines. Coupled with the predominate
localisation of this receptor to immunocytes of haemo-
poetic origin, this receptor is an obvious candidate to play
a major and pivotal role in processes of pain and
inflammation. Using genetically modified animals that
lack the P2X7 receptor, several investigators have shown
t h a tt h e s em i c ed oi n d e e dd e m o n s t r a t eab l u n t e di n f l a m -
matory response, and fail to develop pain following both
inflammatory and neuropathic insult. These animals also
show altered cytokine production in response to inflam-
matory stimulus, which is far broader than merely
modulation of IL-1β release. In this short article, we
review the role of the P2X7 receptor in modulating the
release of cytokines and other mediators, and discuss the
findings made from P2X7 receptor-deficient animals. As
well as highlighting outstanding questions regarding this
intriguing receptor, we also speculate as to the potential
therapeutic benefit of P2X7 receptor modulation.
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Introduction
The P2X7 receptor is an unusual member of the P2X
receptor superfamily. Like the other channels, P2X7 is an
ATP-gated non-selective cation channel, but this receptor
differs from the other members in several important ways.
First, the C-terminal domain of the P2X7 receptor is some
200 amino acids longer than the other members, a feature
that has been hypothesised to confer some of the unusual
functional properties of this receptor. Secondly, the P2X7
receptor can function as a bifunctional receptor, which,
depending on receptor expression and duration and inten-
sity of stimulation (Chessell et al. [1]), appears either as a
non-selective cation channel, or as a large, non-selective
pore with permeability to molecules of molecular mass up
to ∼900 Da. Uniquely in this receptor family, activation of
P2X7 can also activate caspase 1, which causes rapid
release of mature, biologically active interleukin-1β (IL-1β
(Colomar et al. [2]). Whilst the P2X7 receptor was initially
thought to be localised only to cells of the immune system
(Collo et al. [3]), more recent studies suggest a more
diverse distribution (e.g., Narcisse et al. [4]; Zhang et al.
[5]), although some doubts have been raised regarding the
specificity of the tools sometimes used to establish this
localisation (Sim et al. [6]).
Given the localisation and properties of the P2X7
receptor, it is perhaps not surprising that recent data
suggests a pivotal role in initiating or maintaining an
inflammatory response. Whether wholly dependent on this
or mediated by other P2X7 mediated transductional events,
this receptor also appears to play a pivotal role in the
induction or maintenance of both neuropathic and inflam-
matory pain. Here we review these data, and speculate as to
the potential therapeutic indications that P2X7 receptor
antagonists may address.
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As above, P2X7 receptors are found predominantly
expressed in cells of hemopoietic lineage, including
monocytes, macrophages and lymphocytes. Upon appro-
priate activation, this receptor is reported to regulate a
variety of pro-inflammatory cellular signalling events and
has been proposed to serve as a regulator of inflammation
based on its ability to initiate post-translational processing
of leaderless cytokines such as IL-1β and IL-18 (Hogquist
et al. [7]; Sanz et al. [8]). At present it is not completely
clear whether these events depend on the “large pore” form
of the receptor, but there is some data to suggest that very
brief activation of the receptor is sufficient to initiate
cytokine release (Chessell et al. [9]). Upon inflammatory
insult, immune cells generate large quantities of pro-IL-1β
but very little mature biologically active cytokine is
released from the activated cells. Perregaux and Gabel
[10] were the first to demonstrate that ATP potentiates the
post-translational processing and release of IL-1β from
lipopolysacharide (LPS) primed cells. Since then many
studies, both in vitro and in vivo, have demonstrated the
requirement of exogenous ATP to produce large quantities
of active IL-1β and the subsequent impact of this on the
inflammatory response (Griffiths et al. [11]; Solle et al.
[12]). However, the absence of suitable selective pharma-
cological tools has hampered full elucidation of the role
P2X7 plays in this process. Thus, we and others have
generated P2X7 -deficient mice to demonstrate that absence
of the receptor leads to loss of ATP-dependent immune
functions (Chessell et al. [1]; Labasi et al. [13]).
Solle and colleagues were the first to report that in vivo
administration of ATP to LPS primed P2X7 receptor −/−
mice failed to generate significant levels of IL-1β release
from peritoneal macrophages (Solle et al. [12]). In contrast,
wild-type littermates showed a 10-fold increase in biolog-
ically active IL-1β levels. The release of IL-1β is thought
to initiate a signalling cascade leading to the up-regulation
of various other inflammatory mediators such as cyclo-
oxygenase-2 (COX-2), IL-6 and tumour necrosis factor α
(TNFα). Importantly, this group went on to demonstrate
that IL-6 production was also greatly reduced (3-fold
reduction) in the P2X7 −/− mice following exposure to
LPS and ATP, suggesting that blockade of IL-1β release
could impair cytokine signalling cascades in vivo. This
work was further supported by Labasi et al. [13]. Here,
blood samples from P2X7 −/− mouse and wild-type
controls underwent challenge with either ATP or the P2X
agonist, Bz-ATP, following LPS treatment in vitro. Results
similar to those above were obtained with P2X7 −/− mice
showing an absence of IL-1β release compared to wild-
type controls.
LPS-induced IL-1β release was also examined in
thioglycollate-elicited macrophages from both P2X7 −/−
and control animals (Chessell et al. [1]). Six hours
following stimulation with LPS, cultures were stimulated
with Bz-ATP and 30 min later IL-1β was measured in cell
supernatants. No significant release of IL-1β was detected
using cells from the P2X7 −/− animals whilst IL-1β levels
peaked at 700 pg/ml in the control cells following LPS and
BzATP treatment (Fig. 1).
To further elucidate the effect of P2X7 loss on the global
inflammatory response, we profiled local and systemic
cytokine levels in P2X7 −/− and P2X7 +/+ animals 0, 1 and
7 days post intraplantar Freund’s complete adjuvant (FCA)
challenge. Profiling of P2X7 +/+ paw samples revealed a
sustained increase for all cytokines tested (IL-10, IL-1β,
IL-6, MCP-1, TNF-α), with only the increases in IL-1β and
IL-10 being significantly attenuated in the P2X7 −/−
animals across the whole timecourse, indicating that the
effect of P2X7 receptor ligation on down-regulation of
cytokine levels local to insult may be quite selective
(Table 1). In contrast, the IL-6 response was enhanced in
P2X7 −/− animals, suggesting potential compensatory
changes.
These data indicate that P2X7 −/− animals demonstrate
an attenuated cytokine response to FCA challenge. Al-
though the release of IL-1β from P2X7 −/− paws is signifi-
cantly reduced at both 1 and 7 days post-FCA-injection as
compared to control animals, there was no deficit in
IL-1β mRNA expression in the P2X7 −/− paws over the
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Fig. 1 Mature interleukin-1β (IL-1β) release from thioglycolate-
elicited peritoneal macrophages obtained from P2X7 −/− and control
mice. Addition of agonist, Bz-ATP, caused a dose-dependent release
of IL-1β from control animals, LPS-primed cells measured 30 min
following agonist addition, but not from LPS-primed cells from P2X7
−/− animals or non-primed cells from control or P2X7 −/− animals
(adapted from Chessell et al. [1])
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ulation of pro-IL-1β in these animals (Fig. 2). As such, the
P2X7 −/− animals appear to have a normal immune
capability at the transcriptional level but they possess a
deficiency in their ability to process pro-IL-1β in response
to an inflammatory stimulus. This correlates with the
observation that the P2X7 −/− animals possess normal
nociceptive processing but lack the ability to develop
inflammation induced hypersensitivity. A potential mecha-
nism of action may be proposed whereby deletion of P2X7
in vivo is sufficient to block processing of mature IL-1β
and as a consequence block initiation or maintenance of
pathological changes in response to inflammatory insults.
This proposal is further strengthened by the observation
that systemic inflammation following FCA challenge is
abolished in P2X7 −/− animals.
This study also demonstrated that the levels of cell-free
IL-10 are significantly reduced in P2X7 −/− animals as
compared to WT across the time course. The reason for the
decrease in an ‘anti-inflammatory’ cytokine in the P2X7 −/−
animals is not yet clear. However, studies in macrophages
derived from IL-10-deficient animals demonstrate higher
levels of TNF-α production upon activation (Gazzinelli et
al. [14]) indicating an inverse relationship. This is further
supported in the present study, where a transient increase in
levels of TNF-α in the paw samples was also observed in
the P2X7 −/− animals (correlating with a transient increase
in TNF-α gene expression over the time course), indicative
of a synergy between P2X7, IL-1β, IL-10 and TNF-α.I t
also raises the interesting possibility that P2X7 may act
directly upon IL-10, as seen with IL-1β and IL-18 (Mehta
et al. [15]). These observations have been extended by
Fulgenzi et al. [16] who demonstrated reduced IL-10,
MCP-1 and IL-8 levels in inflamed vessels following FCA
injection into rat paw following local use of periodate
oxidised ATP (oATP). These pro-inflammatory chemokines
mediate recruitment of neutrophils, T-cells and monocytes/
macrophages into the inflamed tissues and this data once
again may link P2X7 activation to the inflammatory
process. However, it should be noted that while oATP is
considered an effective antagonist of P2X7, it has been
reported that currents at P2X1 and P2X2 receptors are also
affected (Humphreys et al. [17]). The hypothesis that P2X7
may directly modulate IL-10 and TNF-α as well as IL-1β is
supported by studies on human P2X7 receptor polymor-
phisms. These investigations have revealed a polymor-
phism-dependent modulation of LPS-induced TNF-α and
IL-10 levels in human blood (Denlinger et al. [18]). Blood
samples from individuals with a reduced capacity for
monocyte P2X7 “large pore” formation produced lower
levels of TNF-α as compared to the high pore activity
group following stimulation of the samples with LPS for 6
or 24 h (cytokine levels assessed by ELISA). This
coincided with higher levels of IL-10 in the low “pore”
group and no difference in IL-1β. Although these changes
are different to those observed in P2X7 −/− animals
following FCA injection, it is now important to try and
elucidate fully the mechanism whereby P2X7 channel
activity and/or large pore formation ability affects LPS-
induced IL-10 and TNF-α production, as has been
examined for IL-1β. Importantly, regardless of mechanism,
these data suggest that in the future, relative levels of
specific cytokines in the blood may serve as a surrogate
marker to predict predisposition to inflammatory diseases.
More recently, the signalling events involved in post-
translational processing and release of IL-1β from cells
following P2X7 activation have been investigated. IL-1β
and IL-18 are inactive until cleaved by caspase-1. ATP-
stimulation of P2X7 results in the rapid activation of
caspase-1 in macrophages and the release of mature,
biologically active, IL-1β into the culture medium within
15 min (Mackenzie et al. [19]; Kahlenberg et al. [20]). It
has now been demonstrated that P2X7 receptor activation of
caspase-1 is dependent on the pre-stimulation of macro-
phages with microbially derived ligands for Toll-like
receptors (TLR2/4/9) such as LPS and is dependent on de
novo protein synthesis (cyclohexamide blocks the ability of
LPS to prime cells for P2X7-dependent caspase-1 activa-
Table 1 Released cytokine levels in paw samples from P2X7−/− and P2X7+/+ animals. Data are expressed as % of control values±SEM. FCA
Freund’s complete adjuvant, wt wild type, KO knockout
Time post
FCA (days)
IL-10 IL-1β IL-6 MCP-1 TNFα
wt KO wt KO wt KO wt KO wt KO
0 100±
38.8
100±
4.6
100±
31.2
100±
11.4
100±
6.1
100±15 100±15.3 100±15.0 100±3.1 100±6.4
1 279.7±
26.8
100.7±
4.1*
1,320.8±
84.5
519.7±
76.4*
179.2±
21.4
3,830.1±
717.2*
9,097.7±
942.1
11,005.7±
1,030.3
999.4±
119.0
1,424.7±
271.9
7 272.6±
8.7
120.9±
7.6*
734.2±
18.5
136.8±
11.3*
52.0±
4.5
238.1±
74.7*
13,852.5±
1625.7
8,896.1±
771.0*
1,224.8±
96.9
595.6±
64.9*
*P<0.05, significantly different from WT values, Student’s unpaired t-test, figures in bold
Purinergic Signalling (2007) 3:163–169 165tion) via the NF-kB pathway (Kahlenberg et al. [21]). To
date the proteins that facilitate efficient coupling of caspase-
1 activation to P2X7 stimulation are unclear but their
identification may provide interesting alternative therapeu-
tic targets for inflammatory diseases. One molecule that
may be involved in controlling P2X7 activity is regenera-
tion and tolerance factor (RTF; Derks and Beaman [22]).
RTF is the alpha-2 isoform of the alpha subunit of the
vacuolar ATPase proposed to regulate activity of the
ATPase complex. RTF is expressed on the surface of
activated lymphocytes, constitutively expressed on macro-
phages and is thought to regulate both IL-10 secretion (Lee
et al. [23]) and apoptosis (Boomer et al. [24]). Anti-RTF
antibodies enhance ATP-stimulated IL-1β secretion from
macrophages, block surface ATPase activity and perme-
ability of the cell to PI. These results suggest that RTF may
modulate IL-1β secretion from immune cells by controlling
activation of P2X7. Additional studies have demonstrated a
role for P2X7 in immune cell apoptosis. Bulanova et al.
[25] have shown that addition of extracellular ATP in the
millimolar range induced activation of P2X7 expressed on
murine mast cells, resulting in the rapid but transient
phosphorylation of ERK, Jak2 and STAT6. In addition,
ATP stimulation increased expression levels of IL-4, IL-6,
IL-13 and TNF-α and these effects could be blocked by
pre-treatment of the cells with oATP or KN-62 (a selective
blocker of human and mouse P2X7).
Taken together, the data reviewed here indicates that
P2X7 plays a critical role in the development of inflamma-
tion via modulation of inflammatory mediator production.
As such, drugs that block P2X7 directly, or interact with
proteins that modulate P2X7 activity, may have the
potential to treat a broad range of inflammatory diseases,
including pain associated with inflammation.
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Fig. 2a,b Released IL-1β
and IL-1β mRNA expression
levels for in paw samples from
P2X7−/− and P2X7+/+ animals.
a No deficit in IL-1β mRNA
expression seen in the P2X7−/−
paws over the time-course stud-
ied. b Release of IL-1β from
P2X7−/− paws is significantly
reduced at both 1 and 7 days
post-FCA-injection as compared
to control animals. Data are
expressed as mean values
±SEM. *P<0.05, **P<0.01,
***P<0.001 significantly
different from WT values,
Student’s unpaired t-test
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The in vivo investigation of the role of P2X7 in inflamma-
tion has been hampered by a lack of selective compounds
acting at this receptor (see Baraldi et al. [26]). However,
some work has been published reporting effects of oATP in
rats treated with FCA (Dell’Antonio et al. [27, 28]). FCA
causes a long-lasting hyperalgesia, demonstrated by a
reduction in paw withdrawal thresholds. Injection of oATP
into the treated paw significantly reversed this hyperalgesia,
indicating a putative role for the P2X7 receptor. However,
oATP is known to have actions at receptors other than
P2X7, so it is not possible to unequivocally link the action
of oATP with P2X7 inhibition in these studies. Given the
lack of selective compounds, the development of the P2X7
receptor knockout mouse (P2X7 −/−) has allowed for the
investigation of the role played by this receptor in
inflammation using in vivo animal models. To date, three
reports of such work have appeared.
As mentioned previously, the first study (Solle et al.
[12]) reported that the administration of ATP to LPS primed
P2X7 receptor −/− mice failed to generate significant levels
of mature IL-1β following peritoneal lavage as compared to
the wild-type littermates. No further in vivo data was
reported, with the exception of the fact that the P2X7 −/−
mice appeared to be healthy and fertile. Labasi et al. [13]
also demonstrated that ATP/BzATP stimulation of LPS-
primed blood samples from P2X7 −/− mice in vitro resulted
in markedly less IL-1β release as compared to wild-type
controls. These authors went on to examine the response of
the P2X7 −/− mouse in a monoclonal antibody (mAb)-
induced arthritis model. Here mAbs against collagen were
injected into the mice, which were then injected with LPS.
Following this, wild-type mice developed a severe arthritic
phenotype, which was assessed using a scoring system for
arthritis outcome measures. Under this system each limb
was graded and given a score of 1–4. Mean maximum
severity was then calculated. In these studies, mean
maximum severity scores of 7 were obtained in wild-type
mice. However, the maximum mean score observed in
P2X7 −/− mice was significantly less (<3). Investigations of
cartilage structural integrity were also carried out. This
showed that whilst in the wild-type mice all joints subjected
to mAb-induced arthritis were affected, the P2X7 −/− mice
showed a much lower incidence of pathology.
The behavioural phenotype of the P2X7 −/− mouse was
investigated further by Chessell et al. [1]. In this latter
paper, IL-1β levels were examined following the adminis-
tration of Bz-ATP to LPS primed plated cell cultures, as
discussed above. The effect of P2X7 deletion on the
behavioural phenotype of the mice was demonstrated in
models of both inflammatory and neuropathic pain. In the
first model, P2X7 −/− mice along with wild-type littermate
controls were treated with intraplantar FCA and assessed
for changes in mechanical hypersensitivity using a weight-
bearing averager. Whilst wild-type mice showed a long
lasting hypersensitivity when compared to baseline read-
ings, no difference was observed in P2X7 −/− mice,
indicating a lack of inflammatory response. In the model
of neuropathic pain, mice underwent surgery to partially
ligate the sciatic nerve (Seltzer et al. [29]). Again a
significant level of hyperalgesia was observed in wild-type
mice to both a thermal and a mechanical stimulus, whilst no
significant changes were seen in the P2X7 −/− mice.
Whilst, in the light of the altered cytokine production in
the knockout animals, the lack of development of pain in
the inflammatory model is perhaps not surprising, the
phenotypic differences in the neuropathic pain model were
more unexpected. Whether this phenotype is also resultant
on altered cytokine production, or some other alteration in
signalling is not known. However, in some neuropathic
pain models, the initial development of the pain is driven
by an inflammatory neuritis around the injured nerve, so it
could be hypothesised that the lack of development of pain
in the neuropathy model is again a direct result of an
impaired inflammatory response in the knockout animals.
Taken together, these data indicate that the P2X7
receptor does appear to play a pivotal role in the
development, or maintenance, of pain associated with both
inflammation, and nerve injury. The use of selective
antagonist tools, which are now becoming available
(Alcarez et al. [30]), will help to elucidate the temporal
role of P2X7 in these disease models, as well as answering
any issues regarding the potential for compensatory
changes in knockout animals.
Discussion
The unique properties of the P2X7 receptor, in terms of its
role in mediating the release of biologically active
cytokines, and also its localisation to cells of haemopoetic
origin, makes this receptor an obvious candidate to play a
pivotal role in the inflammatory process. Given that many
inflammatory mediators, including the cytokines, IL-1β and
TNF-α, are able to directly sensitise, or activate, sensory
afferents, it is perhaps no surprise that this receptor also
appears to play a key role in the induction or maintenance
of pain of both inflammatory and neuropathic origin
(Chessell et al. [1]).
Whilst intensive research efforts are beginning to address
the mechanisms by which the P2X7 receptor mediates some
of its effects, many questions remain unanswered. The
exact mechanisms by which the P2X7 receptor undergoes
transformation from a conventional ion channel to the large
Purinergic Signalling (2007) 3:163–169 167pore form remain elusive, although it is hypothesised that
the pore and channel are separate entities (Schilling et al.
[31]), or that there exists both an intrinsic and extrinsic
large pore that is activated by P2X7 (Jiang et al. [32]).
Nonetheless, it is clear that this transition from channel to
pore is not necessarily an absolute requirement for the
release of mature IL-1β (Chessell et al. [1]), although the
events required for the release of TNF-α and IL-10 are less
clear. The actions of the increasing number of cytokines
whose release is modulated by the P2X7 receptor are better
understood; in most cases these cytokines are potent
sensitisers or activators of sensory nerve terminals (and
thus contribute to the generation of pain signalling), and
most also induce expression of further downstream inflam-
matory mediators, or enzyme capable of producing them
(e.g., nitric oxide synthase, cyclooxygenase-2, superoxide
products, nerve growth factor; Woolf et al. [33, 34];
Samad et al. [35]; Parvathenani et al. [36]). Interestingly,
somestudieshavealsodemonstrated thatreleaseofthe“anti-
inflammatory” cytokine, IL-10, is impaired in P2X7−/−
animals (Chessell et al. [1]), which may either be resultant
in changes in concentrations of TNF-α, or perhaps
modulated more directly via the P2X7 receptor.
The phenotypic effects of knockout of the P2X7 receptor
seem to be clear—animals do not develop behaviourally
measurable pain following either inflammatory or neuro-
pathic insult (Chessell et al. [1]), and the incidence and
severity of disease in a model of rheumatoid arthritis is
significantly attenuated (Labasi et al. [13]). Both of these
findings are startling and unusual; there are very few
studies describing the abolition of pain in any other receptor
knockout animals, and such reduction of incidence and
severity of arthritis without general immunocompromisa-
tion is also unusual. However, in both of these studies, it
could not be established, for obvious reasons, whether the
pivotal role of the P2X7 receptor was in the induction or the
maintenance of the pathophysiology associated with these
experimental insults, or perhaps both. It is also important to
bear in mind possible compensatory mechanisms in
continuous knockout animals, which may have a bearing
on the resultant phenotype. The temporal relationship
between activation/inhibition of the P2X7 receptor, and
development or maintenance of inflammation and pain
could be addressed using inducible knockout systems, or
perhaps more readily with selective antagonist molecules. It
is anticipated that these questions will be addressed over the
next few years using either of these approaches.
The lack of development of neuropathic hypersensitivity
in the P2X7 −/− animals was perhaps a little more
surprising, as neuropathic pain is not dogmatically associ-
ated with overt tissue inflammation, and the role of
inflammatory mediators in this pain state is less well
established. However, several studies hypothesise or dem-
onstrate the role of proinflammatory cytokines in the
induction and maintenance of neuropathic pain (see
Lindenlaub and Sommer [37]). Thus, axonal injury does
result in proliferation of inflammatory mediators (see
Holden and Pizzi [38]), which include those associated
with P2X7 receptor activation. Taken together with the
demonstration that the P2X7 receptor has also been shown
to be upregulated in tissues from chronic neuropathic pain
sufferers, the role of this receptor in this disease state does
become more tenable.
The data reviewed in this manuscript suggest that the
P2X7 receptor could be an important upstream regulator of
the inflammatory and pain cascades. Identification and
modulation of such upstream processes for therapeutic
intervention has proved to be challenging; in some cases
discovery of suitable molecular tools has proved to be
intractable (e.g., small molecule IL-1β antagonists), and in
others the pleiotropic effects of modulating the upstream
regulatory machinery has limited the therapeutic benefits in
the clinic (e.g., p38 MAP kinase inhibitors). The ability to
truly modulate both inflammatory and neuropathic pain, as
well as inflammation itself, with small molecule P2X7
antagonists remains to be proven, but data so far suggest a
promising future for this receptor in the treatment of
diseases as diverse as Alzheimer’s disease and inflamma-
tory bowel disease.
References
1. Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green
P, Egerton J, Murfin M, Richardson J, Peck WL, Grahames CBA,
Casula MA, Yiangou Y, Birch R, Anand P, Buell GN (2005)
Disruption of P2X7 purinoceptor gene abolishes chronic inflam-
matory and neuropathic pain. Pain 114:386–396
2. Colomar A, Marty V, Médina C, Combe C, Parnet P, Amédée T
(2003) Maturation and release of interleukin-1b by lipopolysac-
charide-primed mouse Schwann cells require the stimulation of
P2X7 receptors. J Biol Chem 278:30732–30740
3. Collo G, Neidhart S, Kawashima E, Kosco-Vilbois M, North RA,
Buell G (1997) Tissue distribution of the P2X7 receptor.
Neuropharmacology 36:1277–1283
4. Narcisse L, Scemes E, Zhao Y, Lee SC, Brosnan CF (2005) The
cytokine IL-1b transiently enhances P2X7 receptor expression and
function in human astrocytes. Glia 49:245–258
5. Zhang X, Han P, Faltynek CR, Jarvis MF, Shieh C (2005)
Functional expression of P2X7 receptors in non-neuronal cells of
rat dorsal root ganglia. Brain Res 1052:63–70
6. Sim JA, Young MT, Sung H-Y, North RA, Surprenant A (2004)
Reanalysis of P2X7 receptor expression in rodent brain. J
Neurosci 24:6307–6314
7. Hogquist KA, Nett MA, Unanue ER, Chaplin DD (1991)
Interleukin 1 is processed and released during apoptosis. Proc
Natl Acad Sci USA 88:8485–8489
8. Sanz JM, Di Virgilio F (2000) Kinetics and mechanism of ATP-
dependent Il-1beta release form microglial cells. J Immunol
164:4893–4898
168 Purinergic Signalling (2007) 3:163–1699. Chessell IP, Grahames CBA, Michel AD, Humphrey PPA (2001)
Dynamics of P2X7 receptor pore dilation: pharmacological and
functional consequences. Drug Dev Res 53:60–65
10. Perregaux D, Gabel CA (1994) Interleukin 1beta maturation and
release in response to ATP and nigericin: evidence that potassium
depletion mediated by these agents is a necessary and common
feature of their activity. J Biol Chem 269:15195–15203
11. Griffiths RJ, Stam EJ, Downes JT, Otterness IG (1995) ATP
induces the release of IL-1 from LPS-primed cells in vivo. J
Immunol 154:2821–2828
12. Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller
BH, Griffiths RJ, Gabel CA (2001) Altered cytokine production in
mice lacking P2X7 receptors. J Biol Chem 276:125–132
13. Labasi JM, Petrushova N, Donovan C, McCurdy S, Lira P,
Payette MM, Brissette W, Wicks JR, Audoly L, Gabel CA
(2002) Absence of the P2X7 receptor alters leukocyte function
and attenuates an inflammatory response. J Immunol
168:6436–6445
14. Gazinelli RT, Wysocka M, Hieny S, Scharton-Kersten T, Cheever
A, Kuhn R, Muller W, Trinchieri G, Sher A (1996) In the absence
of endogenous IL-10, mice acutely infected with Toxoplasma
gondii succumb to a lethal immune response dependent on CD4+
T cells and accompanied by overproduction of IL-12, IFN-gamma
and TNF-alpha. J Immunol 157:798–805
15. Mehta VB, Hart J, Wewers MD (2001) ATP-stimulated release of
interleukin-1 beta and IL-18 requires priming by lipopolysaccha-
ride and is independent of caspase-1 cleavage. J Biol Chem
276:3820–3826
16. Fulgenzi A, Dell’Antonio G, Foglieni C, Cin ED, Ticozzi P,
Franzone JS, Ferrero ME (2005) Inhibition of chemokine
expression in rat inflamed paws by systemic use of the
antihyperalgesic oxidized ATP. BMC Immunology 6:18
17. Humphreys BD, Rice J, Kertsey SB, Dubyak GR (2000) Stress-
activated protein kinase/JNK activation and apoptopic induction
by the macrophage P2X7 nucleotide receptor. J Biol Chem
275:26792–26798
18. Denlinger LC, Angelini G, Schell K, Green DN, Guadarrama AG,
Prabhu U, Coursin DB, Berties PJ, Hogan K (2005) Detection of
human P2X7 nucleotide receptor polymorphisms by a novel
monocyte pore assay predictive of alterations in lipopolysaccha-
ride-induced cytokine content. J Immunol 174:4424–4431
19. MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA,
Surprenant A (2001) Rapid secretion of IL-1beta by microvesicle
shedding. Immunity 15:825–835
20. Kahlenberg JM, Dubyak GR (2004) Mechanisms of caspase-1
activation by P2X7receptor-mediated K+ release. Am J Physiol
286:C1100–1108
21. Kahlenberg JM, Lundberg KC, Kertesy SB, Qu Y, Dubyak GR
(2005) Potentiation of caspase-1 activation by the P2X7 receptor
is dependent on TLR signals and requires NF-kB-driven protein
synthesis. J Immunol 175:7611–7622
22. Derks R, Beaman K (2004) Regeneration and tolerance factor
modulates the effect of adenosine triphosphate-induced interleu-
kin 1beta secretion in human macrophages. Human Immunol
65:676–682
23. Lee GW, Boomer JS, Gilman-Sachs A, Chedid A, Gudelj L,
Rukavina D, Beaman KD (2001) Regeneration and tolerance
factor of the human placenta induces IL-10 production. Eur J
Immunol 31:687–691
24. Boomer JS, Derks RA, Lee GW, DuChateau BK, Gilman-Sachs
A, Beaman KD (2001) Regeneration and tolerance factor is
expressed during T-lymphocyte activation and plays a role in
apoptosis. Hum Immunol 62:577–588
25. Bulanova E, Budagian V, Orinska Z, Hein M, Petersen F, Thon L,
Adam D, Bulfone-Paus S (2005) Extracellular ATP induces
cytokine expression and apoptosis through P2X7 receptor in
murine mast cells. J Immunol 174:3880–3890
26. Baraldi PG, Di Virgilio F, Romagnoli R (2004) Agonists and
antagonists acting at P2X7 receptor. Curr Top Med Chem
4:1707–1717
27. Dell’Antonio G, Quattrini A, Dal Cin E, Fulgenzi A, Ferrero ME
(2002a) Antinociceptive effects of a new P2Z/ P2X7 antagonist,
oxidised ATP, in arthritic rats. Neurosci Lett 327:87–90
28. Dell’Antonio G, Quattrini A, Dal Cin E, Fulgenzi A, Ferrero ME
(2002b) Relief of inflammatory pain in rats by local use ofthe
selective P2X7 ATP receptor inhibitor, oxidised ATP. Arthritis
Rheum 46:3378–3385
29. Seltzer Z, Dubner R, Shir Y (2000) A novel behavioural model of
neuropathic pain disorders produced in rats by partial sciatic nerve
injury. Pain 43:205–218
30. Alcarez L, Baxter A, Bent J, Bowers K, Braddock M, Cladingboel
D, Donald D, Fagura M, Furber M, Laurent C, Lawson M,
Martimore M, McCormick M, Roberts N, Robertson M (2004)
Novel P2X7 receptor antagonists. Bioorg Med Chem Lett
13:4043–4046
31. Schilling WP, Waylyna T, Dubyak GR, Humphreys BD, Sinkins
WG (1999) Maitotoxin and P2Z/P2X7 puringeric receptor
stimulation activate a common cytolytic pore. Am J Physiol
277:C766–C776
32. Jiang LH, Rassendren F, MacKenzie A, Zhang Y-H, Surprenant
A, North RA (2005) N-methyl-D-glucamine and propridium dyes
utilize different permeation pathways at rat P2X7 receptors. Am J
Physiol 2005:C1295–C1302
33. Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S (1997)
Cytokines, nerve growth factor and inflammatory hyperlagesia:
the contribution of tumour necrosis factor α. Br J Pharmacol
121:417–424
34. Woolf CJ, Ma Q, Allchorne A, Poole S (1996) Peripheral cell
types contributing to the hyperalgesic action of nerve growth
factor in inflammation. J Neurosci 16:2716–2723
35. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole
S, Bonventre JV, Woolf CJ (2001) Interleukin-1b-mediated
induction of Cox-2 in the CNS contributes to inflammatory pain
hypersensitivity. Nature 410:471–475
36. Parvathenani LK, Tertyshnikova S, Greco CR, Roberts SB,
Robertson B, Posmantur R (2003) P2X7 mediates superoxide
production in primary microglia and is up-regulated in a
transgenic mouse model of Alzheimer’s disease. J Biol Chem
278:13309–13317
37. Lindenlaub T, Sommer C (2000) Partial nerve transection as a
model of neuropathic pain: a qualitative and quantitative neuro-
pathological study. Pain 89:97–106
38. Holden JE, Pizzi JA (2003) The challenge of chronic pain. Adv
Drug Del Rev 55:935–948
Purinergic Signalling (2007) 3:163–169 169